Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dutasteride + ethanol is a topical formulation of the dual 5-alpha-reductase inhibitor dutasteride, primarily investigated for the treatment of androgenetic alopecia (male pattern hair loss). In this formulation, ethanol serves as a solvent and penetration enhancer, facilitating the delivery of the relatively large dutasteride molecule (MW 528.5) through the stratum corneum into the hair follicles. By inhibiting both Type 1 and Type 2 isoforms of 3-oxo-5-alpha-steroid 4-dehydrogenase, the drug reduces the local conversion of testosterone to dihydrotestosterone (DHT), the primary androgen responsible for follicle miniaturization. Topical administration is intended to provide localized therapeutic effects while minimizing systemic exposure and the associated side effects, such as sexual dysfunction, that are commonly observed with oral 5-alpha-reductase inhibitors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dutasteride + ethanol.